ARX
AROA BIOSURGERY ORDINARYAroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX
ARX
AROA BIOSURGERY ORDINARY
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds.
Fundamentals
Historical Data51 days
| Date | Short % | Gross Short |
|---|---|---|
| 23 Sept | 0.00% | — |
| 8 Sept | — | — |
| 7 Sept | — | — |
| 4 Sept | — | — |
| 3 Sept | — | — |
| 2 Sept | — | — |
| 1 Sept | — | — |
| 31 Aug | — | — |
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | — | — |
Aroa Biosurgery (ARX) Short Interest Summary
Aroa Biosurgery (ARX) currently has 0.00% of its shares sold short (8 thousand shares, worth approximately $4K), based on ASIC short position data reported on 23 September 2026 (T+4 reporting lag). That makes ARX the #650 most shorted stock on the ASX most shorted list. Short interest in ARX is up 0.00% over the past week and up 0.00% over the past month. ARX is part of the Health Care sector on the ASX.
Recent ARX Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 23 Sept 2026 | 0.00% | 0.0M | — |
| 10 Aug 2026 | 0.00% | 0.0M | $0.61 |
| 7 Aug 2026 | 0.00% | 0.0M | $0.56 |
| 6 Aug 2026 | 0.00% | 0.0M | $0.56 |
| 5 Aug 2026 | 0.00% | 0.0M | $0.56 |
| 4 Aug 2026 | 0.00% | 0.0M | $0.55 |
| 3 Aug 2026 | 0.00% | 0.0M | $0.56 |
| 31 July 2026 | 0.00% | 0.0M | $0.57 |
| 30 July 2026 | 0.00% | 0.0M | $0.56 |
| 29 July 2026 | 0.00% | 0.0M | $0.58 |
ARX Short Selling — Frequently Asked Questions
What is Aroa Biosurgery (ARX)'s current short interest?
Aroa Biosurgery (ARX) currently has a short interest of 0.00% of total shares outstanding. This means 0.00% of ARX's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is ARX heavily shorted on the ASX?
ARX has a relatively low short interest of 0.00%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for ARX investors?
Short interest in ARX shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.00%, ARX's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this ARX short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for ARX.